Literature DB >> 20589485

Managing comorbid disease in patients with psoriatic arthritis.

M Elaine Husni1, Philip J Mease.   

Abstract

Psoriatic arthritis (PsA) is a unique type of inflammatory arthritis that is associated with skin psoriasis. The concept that PsA is simply a skin and joint disease has been challenged by large epidemiologic studies that link PsA with substantial comorbidity. Important comorbidities related to PsA include premature cardiovascular disease, infectious complications, malignancy risk, osteoporosis, and reduced quality of life. This review focuses on the prevalent comorbid diseases in patients with PsA and highlights how the presence of these associated comorbidities can affect the management of these patients.

Entities:  

Mesh：

Year:  2010        PMID： 20589485     DOI： 10.1007/s11926-010-0112-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  32 in total

Review 1.  Metabolic disorders in patients with psoriasis and psoriatic arthritis.

Authors:  Lotus Mallbris; Christopher T Ritchlin; Mona Ståhle
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 2.  The psychosocial burden of psoriasis.

Authors:  Alexa B Kimball; Christine Jacobson; Stefan Weiss; Mary G Vreeland; Ying Wu
Journal:  Am J Clin Dermatol       Date:  2005       Impact factor: 7.403

3.  Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis.

Authors:  Oded Kimhi; Dan Caspi; Natan M Bornstein; Nitsan Maharshak; Alexander Gur; Yaron Arbel; Doron Comaneshter; Daphna Paran; Irena Wigler; David Levartovsky; Shlomo Berliner; Ori Elkayam
Journal:  Semin Arthritis Rheum       Date:  2006-10-25       Impact factor: 5.532

4.  Bone mineral density in patients with psoriatic arthritis.

Authors:  B Frediani; A Allegri; P Falsetti; L Storri; S Bisogno; F Baldi; P Filipponi; R Marcolongo
Journal:  J Rheumatol       Date:  2001-01       Impact factor: 4.666

5.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Authors:  Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala
Journal:  J Rheumatol       Date:  2006-09-01       Impact factor: 4.666

6.  Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis.

Authors:  B J Harrison; C E Hutchinson; J Adams; I N Bruce; A L Herrick
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

7.  Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry.

Authors:  Soumya M Reddy; Allen P Anandarajah; Mark C Fisher; Philip J Mease; Jeffrey D Greenberg; Joel M Kremer; George Reed; Rui Chen; Susan Messing; Kimberly Kaukeinen; Christopher T Ritchlin
Journal:  J Rheumatol       Date:  2010-09-15       Impact factor: 4.666

8.  Bone mineral density and bone turnover in patients with psoriatic arthritis.

Authors:  Pinar Borman; Seçil Babaoğlu; Guneş Gur; Sezin Bingol; Hatice Bodur
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

9.  Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only : results of the 2005 Spring US National Psoriasis Foundation Survey.

Authors:  David H Ciocon; Elizabeth J Horn; Alexa B Kimball
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

10.  Prevalence of malignancy in psoriatic arthritis.

Authors:  Sherry Rohekar; Brian D M Tom; Agnes Hassa; Cathy T Schentag; Vernon T Farewell; Dafna D Gladman
Journal:  Arthritis Rheum       Date:  2008-01
View more
  5 in total

1.  Addressing comorbidities in psoriatic disease.

Authors:  Priya Patel; Cheryl F Rosen; Vinod Chandran; Yang Justine Ye; Dafna D Gladman
Journal:  Rheumatol Int       Date:  2017-11-28       Impact factor: 2.631

2.  Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.

Authors:  Marta Fantò; Mario Stefano Peragallo; Mario Pietrosanti; Roberta Di Rosa; Andrea Picchianti Diamanti; Simonetta Salemi; Raffaele D'Amelio
Journal:  Intern Emerg Med       Date:  2015-06-23       Impact factor: 3.397

3.  Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain.

Authors:  Juan Carlos Torre-Alonso; Loreto Carmona; Mireia Moreno; Eva Galíndez; Jesús Babío; Pedro Zarco; Luis Linares; Eduardo Collantes-Estevez; Manuel Fernández Barrial; Juan Carlos Hermosa; Pablo Coto; Carmen Suárez; Raquel Almodóvar; Jesús Luelmo; Santos Castañeda; Jordi Gratacós
Journal:  Rheumatol Int       Date:  2017-04-07       Impact factor: 2.631

4.  A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.

Authors:  Rachael L Gross; Julie S Schwartzman-Morris; Michael Krathen; George Reed; Hong Chang; Katherine C Saunders; Mark C Fisher; Jeffrey D Greenberg; Chaim Putterman; Philip J Mease; Alice B Gottlieb; Joel M Kremer; Anna Broder
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

Review 5.  Psoriasis: new comorbidities.

Authors:  Jackson Machado-Pinto; Michelle dos Santos Diniz; Nádia Couto Bavoso
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.